Bionomics in technology partnership with PerkinElmer
11 May, 2004 by Graeme O'NeillAdelaide epilepsy specialist Bionomics (ASX:BNO) has announced a yin-yang collaboration with international drug-discovery, life-science research and analytical solutions company PerkinElmer.
Winter's way: why Domantis still leads in antibody technology
07 May, 2004 by Renate KrelleEngineer Greg Winter spends his days building, folding chains and working with scaffolds. He's also a librarian. But rather than cataloguing hefty manuscripts, he has viruses create each new inventory for him -- an elegant manufacturing process if ever there was one.
Prana to raise $27m from US investors
28 April, 2004 by Melissa TrudingerPrana Biotechnology (ASX:PBT) has obtained agreements to raise US$20 million (AUD$27 million) from US institutional and professional investors through the sale of 3 million ADRs at US$5 per ADR, subject to shareholder approval.
Bacterial parasite shows potential in disease control
21 April, 2004 by Lon BramThe recently completed Wolbachia pipientis gene sequence is paving the way to understanding this parasite's interaction with its insect hosts.
Optiscan breaks silence with new clinical results
19 April, 2004 by Renate KrelleMelbourne-based Optiscan Imaging (ASX:OIL) has emerged from a quiet patch with the first results from a series of clinical studies using its flexible endomicroscopes.
NHMRC gives green light to embryo research
16 April, 2004 by Renate KrelleAustralia's first licences allowing research using excess human embryos were issued today by the National Health and Medical Research Council's embryo research licensing committee.
Smile, baby -- those teeth are lifesavers
08 April, 2004 by Graeme O'NeillIn future, the tooth fairy may leave children something more than a silver coin in a glass of water, in exchange for their lost milk teeth. Researchers at the Hanson Institute in Adelaide believe pluripotent stem cells from those deciduous teeth could help sustain their owners' dental, skeletal, neural and cardiovascular health well into the autumn of their lives.
Sydney researchers uncover cancer's silent culprit
07 April, 2004 by Graeme O'NeillTwo Sydney cancer patients have made medical history this week as the first individuals to be diagnosed with cancer induced by spontaneous silencing of an otherwise normal tumour-suppressor gene.
Billionaire gives $20 million to UQ, Foundation gives $3.3 million to cancer projects
01 April, 2004 by Graeme O'NeillIf Queensland Premier Peter Beattie fulfils his ambition of appropriating Victoria’s mantle as the Biotech State, he will be indebted to itinerant Brisbane resident Chuck Feeney.
London-Brisbane vaccine research extended to kidney cancer
01 April, 2004 by Renate KrelleHaving secured patent coverage for its vaccine technology, London-based Onyvax will extend its collaboration with researchers from the Queensland University of Technology and the Princess Alexandra Hospital.
Novogen's phenoxodiol shows promise in cancer trials
01 April, 2004 by Melissa TrudingerNovogen (ASX: NRT) has announced updated results from two clinical trials of its anti-cancer drug phenoxodiol, which is being developed by the company's US-based subsidiary Marshall Edwards (LSE AIM: MSH; Nasdaq: MSHL).
GTG awarded further patents and forensic accreditation
29 March, 2004 by Melissa TrudingerGenetic Technologies' (ASX: GTG) non-coding DNA analysis and foetal cell separation patents have been allowed by the Canadian Patent Office -- almost 15 years after the company filed its first non-coding DNA patent.
Virax raises $3.7 million in placement
26 March, 2004 by Melissa TrudingerVirax (ASX: VHL) announced this week that it had raised AUD$3.7 million through a placement to institutional and professional investors.
Prima could net $20m in deal with Canada's Biomira
11 March, 2004 by Renate KrelleCommercialisation proceeds apace at Prima Biomed, which today announced an agreement with Canadian cancer vaccine specialist Biomira.
Promics completes psoriasis pilot study
10 March, 2004 by Melissa TrudingerBrisbane-based biotechnology company Promics has completed a pilot study examining the safety of its lead anti-inflammatory drug PMX 53 as a topical treatment for psoriasis.
